CD7/SIRα is an important innate immune checkpoint in cancer, and one study found that high SIRPA expression was associated with a favorable response to anti-PD-1 therapy [61], which explains the downregulation of SIRPA in the high-risk group. The gene discussed is SIRPA; the disease is cancer.